65.05
+9.73%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About 10X Genomics
From its filings with the US Securities and Exchange Commission
10X Genomics is based in Pleasanton, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TXG. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $642.8m and a net loss of $43.5m. At that date it held total assets of $1.04bn and shareholders' equity of $796.3m. By region, Americas accounted for 55.8%, followed by Europe, Middle East and Africa at 25.2% and Asia-Pacific at 19.0%.
Our mission is to accelerate the mastery of biology to advance human health. We are a life sciences technology company focused on building innovative products and solutions to interrogate, understand and master biology. Our integrated research solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. We have built deep expertise across diverse disciplines including chemistry, biology, hardware and software. Innovations in all of these areas have enabled the deployment of our rapidly expanding suite of products, which allow our customers to interrogate biological systems at previously inaccessible resolution and scale. Our products have enabled researchers to make fundamental discoveries across multiple areas of biology, including oncology, immunology and neuroscience.
Since launching our first product in mid-2015 through December 31, 2025, we have sold 8,046 instruments to researchers around the world, including academic and translational researchers and biopharmaceutical companies. Our revenue was $642.8 million and $610.8 million for the years ended 2025 and 2024, respectively, representing a year-over-year increase of 5%. We generated net losses of $43.5 million and $182.6 million for the years ended 2025 and 2024, respectively. In the years ended December 31, 2025 and 2024, we sold 1,007 and 1,073 instruments and 424,000 and 357,100 consumable reactions, respectively.
Quoted from its 10-K, filed 13 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 12 Sept 2019
- Employees
- 1,178
- Website
- 10xgenomics.com ↗
- Head office
- 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588
- Incorporated in
- DE
- Classification
- Laboratory Analytical Instruments
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. John StuelpnagelIndependent Chairman of the Board$318,302
- Dr. Benjamin HindsonPresident, Co-Founder, Chief Scientific Officer, Director, since 2012$4.3m
- Mr. Serge SaxonovChief Executive Officer, Co-Founder, Director, since 2012$7.9m
- Mr. Adam TaichChief Financial Officer$3.3m
- Mr. Eric WhitakerChief Legal Officer$7.0m
- Mr. Sridhar KosarajuIndependent Director$263,458
- Mr. Alan MateoIndependent Director$477,994
- Ms. Kimberly PopovitsIndependent Director$258,052
- Dr. Shehnaaz SulimanIndependent Director$251,755
- Dr. Sarah TeichmannIndependent Director$469,852
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 28
- Environment
- 32
- Social
- 19
- Governance
- 33
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Technological Innovation: 10X Genomics Inc is known for its cutting-edge technology in single-cell genomics. Their innovative solutions enable researchers to gain unprecedented insights into complex biological systems.
- Broad Product Portfolio: The company offers a wide range of products and solutions, including instruments, consumables, and software, catering to various research needs in genomics and transcriptomics.
- Strong Customer Base: 10X Genomics has established a strong customer base globally, including leading academic institutions and pharmaceutical companies, with high customer satisfaction and loyalty.
- Strategic Partnerships: The company has forged strategic partnerships with key players in the genomics industry, enhancing its market presence, expanding distribution networks, and fostering collaborations.
Weaknesses
- High Pricing: The advanced technologies offered by 10X Genomics come at a premium price, limiting accessibility for smaller research institutions or budget-constrained customers.
- Dependence on Research Funding: The company's revenue is significantly dependent on research grants and funding, which are subject to fluctuations and uncertainties, impacting financial stability.
- Limited Global Market Penetration: While the company has established a strong presence in certain regions, its market penetration in other geographical areas may be relatively low, indicating room for further growth.
Opportunities
- Increasing Demand for Genomic Research: The growing interest in personalized medicine and the need for understanding complex diseases present tremendous opportunities for 10X Genomics to expand its customer base and market share.
- Mergers & Acquisitions: The company can explore strategic acquisitions or partnerships to enhance its product offerings, access new technologies, and strengthen its competitive position in the genomics market.
- Expansion into Emerging Markets: 10X Genomics can focus on expanding its operations into emerging markets where the adoption of genomics research is on the rise, opening up new revenue streams.
Threats
- Intense Competition: The genomics industry is highly competitive, with several established players and new entrants competing for market share, posing a threat to 10X Genomics' growth and profitability.
- Regulatory Challenges: Evolving regulations and compliance requirements in the genomics sector could increase operational complexities and costs for 10X Genomics, limiting its ability to address certain markets.
- Technological Advancements by Competitors: The rapid pace of technological advancements by competitors may pose a threat to 10X Genomics' market position if it fails to innovate and stay at the forefront of new developments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.